Understanding these different mechanisms and molecular players underlying -syn spread is crucial for the development of therapies that could halt the progression of -syn-related degenerative diseases.
Introduction
Parkinson's disease (PD) is characterized by the presence of protein aggregates termed Lewy bodies (LBs) when located in neuron soma, and Lewy neurites (LNs) when located in axons. Both consist mainly of misfolded and fibrillar forms of alpha-synuclein (-syn) (Spillantini et al., 1997) , a protein located predominantly at pre-synaptic terminals where it is soluble and appears to play a role in the homeostasis of the synaptic vesicle pool (Burré et al., 2010; Chandra et al., 2005; Murphy et al., 2000; Withers et al., 1997) . When aggregated in LBs and LNs, α-syn displays characteristics of amyloids and is assembled into highly ordered fibrils (Spillantini et al., 1998a) . Besides PD, α-syn aggregation is also characteristic of dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). These neurodegenerative diseases are now collectively referred to as synucleinopathies (Baba et al., 1998; Spillantini et al., 1997; 1998b; Wakabayashi et al., 1998 ).
The Braak model of PD posits that LBs and LNs spread with time between
axonally connected structures in the PNS and CNS (Braak et al., 2006; 2003) .
This model and the prion hypothesis for synucleinopathies are game-changing concepts with implications for both our understanding of the pathogenesis of PD and the development of new therapies. The model has been bolstered by a growing number of studies showing that -syn fibrils can spread through connected neuronal networks, and seed the misfolding of endogenous α-syn after internalization by neurons (Luk et al., 2012a; Volpicelli-Daley et al., 2011 ).
Here we review the successive steps (internalization, transport and exit) necessary for the spread of α-syn fibrils. The initial misfolding, oligomerization and fibrillization, which triggers the disease, will be touched on only briefly in this introduction. It is assumed that the initial fibrillization results from stochastic α-syn misfolding that is not properly dealt with by quality control mechanisms. It may be favored by high local concentration of the protein in certain vulnerable neuron populations. This may be the case in individuals with duplications and A C C E P T E D M A N U S C R I P T 4 triplications of the α-syn gene (SNCA), or genetic variants located in non-coding genomic regions, which enhance α-syn expression (Ibáñez et al., 2004; Simón-Sánchez et al., 2009; Singleton et al., 2003; Soldner et al., 2016 ).
Here we review the knowledge on three steps -internalization, transport and exit of α-syn fibrils -central to the spread of α-syn pathology. We will focus on studies that use α-syn fibrils isolated from patient CNS or obtained in vitro from bacterially-expressed recombinant protein (preformed fibrils, PFFs), thereby bypassing the initial seed formation. We will limit the discussion to fibrillar forms of α-syn since only those forms have been shown to trigger the aggregation of endogenous α-syn robustly both in vitro and in vivo Luk et al., 2012a; 2012b; Paumier et al., 2015; Peelaerts et al., 2015; Volpicelli-Daley et al., 2011) . Understanding uptake transport and release of α-syn fibrils will not only further our understanding of the progressive nature of synucleinopathies but may also uncover potential targets for therapeutic intervention that could slow or even halt the spread of α-syn pathology.
The uptake of α-syn fibrils by neurons
Primary neurons cultured in vitro rapidly internalize recombinant α-syn fibrils that are added to the medium (Abounit et al., 2016; Brahic et al., 2016; VolpicelliDaley et al., 2011) . In the mouse, α-syn fibrils administered by stereotaxic injection into the brain are taken up within a few hours by neurons and glia surrounding the injection site (N. L. Rey et al., 2013) . Uptake can take place both in the soma/dendrites as well as the axon compartment, as shown using microfluidic tissue culture devices that physically separate soma/dendrites from axons (Brahic et al., 2016; Freundt et al., 2012; Tran et al., 2014; Volpicelli-Daley et al., 2011) . The extent and the kinetics of uptake reported by different laboratories appear to vary, which could be due to differences in culture conditions and/or the method of sonication used to fragment the fibrils. Furthermore, differences can also be attributed to the use of distinct "α-syn
strains" with varying biophysical properties Guo et al., 2013; Sacino et al., 2014) .
There is strong evidence that α-syn PFFs enter cell lines and primary neurons in culture by endocytosis (Figure 1 ). Inhibiting endocytosis with low temperature or by expressing a dominant negative version of dynamin 1, markedly reduces the uptake (Desplats et al., 2009 ; H.-J. Lee et al., 2005a; 2008) . Internalized α-syn PFFs co-localize with both early endosomal markers EEA1 and Rab5 and late endosomal/lysosomal marker Rab7 and Lamp1 (Brahic et al., 2016; Desplats et al., 2009; Konno et al., 2012 ; H.-J. Lee et al., 2008) . The majority of endocytosed α-syn PFFs appears to be degraded in lysosomes.
However, there are some conflicting reports about the kinetics of degradation, possibly due to variations in cell culture systems, fibril preparations and methods of delivery (H.-J. Lee et al., 2008; Luk et al., 2009) Interestingly, the uptake of α-syn fibrils by neurons may have striking commonalities with the entry of viruses into host cells. Many viruses first bind to heparan sulfates on the cell surface in what is believed to be a non-specific electrostatic interaction (Marsh and Helenius, 2006) . Subsequently, the interaction with one, or more, specific protein receptor(s) triggers protein conformation changes that lead to entry through the plasma membrane. In the case of α-syn fibrils, as well as misfolded tau and PrP, it has been shown that the proteins bind heparan sulfate proteoglycans (HSPGs) on the surface of cells (Figure 1) (Holmes et al., 2013; Horonchik et al., 2005; Schonberger et al., 2003; Shrivastava et al., 2015) . Holmes et al. demonstrated that internalization by nonneuronal cell lines was reduced by competitive inhibition with heparin. Although blocking the HSPG-α-syn interaction using heparin or heparin mimics is an intriguing potential therapeutic approach, it will be important to examine if the uptake of α-syn PFFs is mediated by HSPGs in CNS neurons.
In addition to HSPGs, a variety of cell surface proteins that bind α-syn fibrils with some specificity have recently been identified (Figure 1) . Mao et al. expressed a trans-membrane protein cDNA library in the SH-SY5Y cell line and screened for differential binding to α-syn fibrils over α-syn monomers. Although
only a fraction of the transmembrane proteins in the library were known to locate to the plasma membrane, the authors identified several putative receptors for fibrillary α-syn including neurexin 1 and APLP1 but eventually focused on the product of lymphocyte-activation gene 3 (LAG3) (Mao et al., 2016) . Using knockout and over-expression systems, they showed that LAG3 is involved in the binding and endocytosis of α-syn PFFs. The absence of LAG3 reduced but did not completely abolish α-syn aggregation and spread in primary neurons as well as in the mouse CNS. LAG3-specific antibodies competitively blocked the interaction and reduced the uptake of α-syn fibrils by cultured neurons and, as a result, prevented the fibrilization of endogenous α-syn. Although the authors indicate that LAG3 is predominantly expressed by neurons, published gene expression datasets show that it is highly expressed by microglia, potentially mediating α-syn fibril uptake by these glial cells . These important results point to LAG3 as a potential drug target, although it is currently not known whether α-syn is expressed on relevant human neuronal populations.
In addition to LAG3, other cell surface proteins expressed by neurons have been shown to bind α-syn fibrils. In particular, the Na+/K+ transporting ATPase subunit α3 (α3-NKA) was found in an unbiased proteomics study aimed at identifying neuronal cell-surface binding partners of recombinant α-syn fibrils and oligomers (Shrivastava et al., 2015) . Interestingly, ATP1A3, the gene encoding α3-NKA, is linked to rapid-onset dystonia-parkinsonism ( receptor or the receptor-fibril complex that would somehow cause transfer (Igonet and F. A. Rey, 2012) . Escape from the endosomal lumen could be a relatively rare, rate-limiting event that contributes to the chronicity of PD. Distinct α-syn 'strains' may have different affinities for surface proteins causing differences in their ability to escape the endosomal compartment.
The uptake of α-syn fibrils, including binding to surface proteins, endocytosis and escape from endosomal compartment, could be targeted by drugs to slow down or even prevent neuron-to-neuron transmission of pathology.
Identifying as many putative targets as possible will be important in the hope that some may be specific enough to the entry of α-syn to avoid general toxicity.
The axonal transport of α-syn fibrils
The evidence for the axonal transport of misfolded α-syn comes from experiments done in vivo, in the mouse, and in vitro using cultured neurons. In the mouse, several groups showed that injecting preformed fibrillar α-syn, or α-syn fibrils extracted form PD CNS material, induces the fibrillization of endogenous α-syn at the site of injection, as well as in distant brain areas (Luk et al., 2012b; 2012a; Masuda-Suzukake et al., 2013; Mougenot et al., 2012; Paumier et al., 2015; Peelaerts et al., 2015; Recasens et al., 2014) . Mapping these remote secondary sites showed that they were connected to the site of injection by anterograde and retrograde axonal projections. These results,
predicted by the Braak model (Braak et al., 2003) , are consistent with axonal transport of fibrils and seeding of misfolding at a distance in secondary neurons, although they do not formally prove it.
Direct observation of axonal transport of α-syn fibrils was obtained using primary mouse neurons grown in microfluidic devices, which physically separate the soma and axonal compartments in two fluidically isolated channels. In this way, if a product added, for example, to the soma compartment appears in the axon compartment it must have been actively transported by the axons, in this case in the anterograde direction. Using this approach, transport of exogenously added preformed oligomeric misfolded α-syn and α-syn fibrils was observed in both the anterograde and retrograde direction (Figure 2 ) (Brahic et al., 2016; Danzer et al., 2011; Freundt et al., 2012) . Measuring the amount of labeled, preformed fibrils transported in either direction showed that retrograde transport was almost twice as efficient as anterograde transport (Brahic et al., 2016) .
Time-lapse microscopy provided a measurement of transport velocity. In the anterograde direction, the fibrils moved at velocities characteristic of fast axonal transport but with pauses of variable lengths, a behavior that defines slow component b of axonal transport. This type of transport moves large assemblies of axonal proteins not enclosed in vesicles (Roy et al., 2007) . It was suggested that α-syn fibrils might have properties in common (size, charge, other surface showed that the DnaJ/Hsc70 chaperone complex could drive the secretion by neurons of α-syn and of other neurodegenerative-associated proteins such as tau and TDP43. The structure, misfolded or not, of α-syn secreted by these pathways was not determined (Fontaine et al., 2016; J.-G. Lee et al., 2016) . At present we do not know if the USP19 and DnaJ/Hsc70 pathways are synergistic or work in parallel. If they operate for the release of misfolded, oligomeric or fibrillar forms of α-syn they may offer new drug targets for PD.
The release of α-syn fibrils by neurons has been investigated using primary neurons cultured in microfluidic devices (Brahic et al., 2016; Freundt et al., 2012) . Fluorescently labeled fibrils were released into the medium after both anterograde and retrograde axonal transport (Figure 3 ). Since release after anterograde transport was unaffected by the Sarm1 -/-and WLD S mutations,
which render axons highly resistant to degeneration, the fibrils likely were secreted into the medium independent of cell lysis (Brahic et al., 2016) . In CNS, where many axons are myelinated or surrounded by other types of glial cells, secretion may be restricted to areas with high endo-and exocytic activity such as synaptic terminals.
Microfluidic devices were also used to show that α-syn PFFs released in the medium after anterograde transport are internalized by still immature second order neurons (Freundt et al., 2012) . Using three chamber microfluidics devices, it was recently shown that PFF added to the first chamber can trigger aggregation of endogenous α-syn in synaptically connected neurons in the second and third chamber, indirectly demonstrating the release and transmission of pathological α -syn species in neuronal networks in vitro (Mao et al., 2016; Tran et al., 2014) . Importantly, the aggregation was reduced when certain anti-α-syn monoclonal antibodies were added to the medium. Moreover, the same systemically-administered antibodies were able to reduce the pathology induced by intracerebral injection of α-syn PFFs in mice (Tran et al., 2014) . Accessibility to antibodies suggests that α-syn fibrils are not secreted in vesicles and raises the hope of being able to interfere with spread by using soluble extracellular drugs.
The role of exosomes and tunneling nanotubes in neuron-to-neuron transfer of α-syn fibrils
α-syn seeds may also use routes other than direct secretion in the extracellular space to spread from neuron-to-neuron. In particular, soluble and oligomeric forms of α-syn have been found in exosomes (Figure 3) . However, there is no data yet demonstrating the presence of α-syn fibrils in exosomes. Overall, the amount of α-syn in exosomes appears to be relatively low, significantly smaller than the amount secreted by exocytosis (Alvarez-Erviti et al., 2011; Emmanouilidou et al., 2010) . Additionally, there is no evidence that α-syn-
containing exosome can trigger aggregation of endogenous α-syn in recipient neurons. Interestingly, lysosomal impairments have been associated with PD and exosome secretion has been shown to increase in response to lysosomal dysfunction (Budnik et al., 2016; Zappulli et al., 2016) . Additionally, PDassociated risk genes are involved in intracellular vesicle traffic and transport to lysosomes (Abeliovich and Gitler, 2016; Mazzulli et al., 2016) . It is thus possible that fibrils are more prominent in exosomes in these risk gene associated cases of PD. The PD-linked gene ATP13A2 (PARK9), establishes a more direct link between exosomes and α-syn. Indeed, over-expression of PARK9 in neurons causes increased exosome-mediated release of α-syn (Tsunemi et al., 2014) .
Tunneling nanotubes, F-actin containing membranous bridges that can connect cells to each other, have been hypothesized to mediate the transmission of α-syn fibrils between neurons (Abounit and Zurzolo, 2012) . Evidence has accumulated that the prion protein PrP can spread from cell to cell by way of tunneling nanotubes (Gousset et al., 2009 ). More recently, Abounit et al. (2016) showed that fibrillar α-syn could also use tunneling nanotubes to spread from cell to cell and seed fibrillization in the recipient cell in vitro (Abounit et al., 2016) . In summary α-syn fibrils may be released form neurons via several pathways (Figure 3 ). Non-conventional secretion of naked fibrils is now well documented.
Exosomes and tunneling nanotubes may participate in the release, most probably to a smaller extent than non-conventional secretion. However, the exact state of α -syn, whether monomeric, oligomeric or fibrillar, as well as the exact molecular players mediating these processes remain to be investigated.
Concluding Remarks
The entry into neurons, axonal transport and release of misfolded α-syn are central steps in the pathogenesis of PD. Now the challenge is to define the mechanisms underlying these steps in detail, at the molecular level. This review described recent advances made towards this goal. The identification of candidate receptors for entry, the characterization of the kinetics and yield of The future of the field is exciting. Fundamental questions in neurobiology will be solved and it is hoped that the answers will help devise new treatments for this very common neurodegenerative disease. 
